Atea Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AVIR Nasdaq 8731 https://ateapharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atea Pharmaceuticals Inc

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients - Mar 27th, 2024 11:00 am
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript - Feb 29th, 2024 3:03 pm
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results - Feb 28th, 2024 9:58 pm
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Feb 28th, 2024 9:05 pm
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 - Feb 21st, 2024 12:00 pm
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study - Jan 10th, 2024 2:30 pm
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 - Jan 8th, 2024 9:05 pm
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2024 12:00 pm
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 - Nov 13th, 2023 12:00 pm
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript - Nov 9th, 2023 8:57 pm
Q3 2023 Atea Pharmaceuticals Inc Earnings Call - Nov 9th, 2023 10:48 am
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Nov 8th, 2023 9:05 pm
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Nov 8th, 2023 12:00 pm
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 - Nov 2nd, 2023 11:00 am
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 - Nov 1st, 2023 11:00 am
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Oct 24th, 2023 4:30 pm
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference - Sep 6th, 2023 11:00 am
Q2 2023 Atea Pharmaceuticals Inc Earnings Call - Aug 9th, 2023 10:58 am
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - Aug 8th, 2023 8:05 pm
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 - Aug 1st, 2023 11:00 am